Author

Editorial director of PeptideClear. Oliver oversees editorial standards, source-checking, named-prescriber coordination, and the conflict-of-interest framework across every page on the site. He is also a director of Best Business Loans Ltd, the UK company that owns and operates PeptideClear.

Editorial principles

Five principles govern every page on this site. They are non-negotiable and override any commercial consideration.

• 1. Encyclopedia framing, not clinical advice. PeptideClear is a comparison and information service, not a clinic. We do not prescribe, dispense, or recommend a specific medication or dose to a specific person. Every editorial position ends at "your prescriber decides".
• 2. Source-trail audit. Every NICE, MHRA, NHS or PIL claim is traceable to the source document. We do not paraphrase guidance from secondary sources where the primary is accessible.
• 3. No health claims on research peptides. Research peptides are sold in the UK under "research use only" framing. Editorial treatment is encyclopedic: what the molecule is, what the preclinical literature shows, what UK regulatory status is. No dosing protocols, no human-use instructions, no therapeutic claims.
• 4. Affiliate disclosure on every commercial page. Where PeptideClear earns a referral fee, the page carries an inline affiliate disclosure. Inclusion in rankings is not contingent on a referral relationship.
• 5. No before-and-after weight-loss imagery. ASA position on consumer-facing GLP-1 advertising restricts this and we apply the same standard editorially.

Source hierarchy

When sources disagree, we treat them in this order of authority:

1. MHRA-approved Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for the specific medicine.
2. Published NICE technology appraisal or clinical guideline (NG, TA, MTG).
3. Peer-reviewed primary research, with preference for independent over industry-funded.
4. Published NHS England commissioning guidance or ICB statements.
5. Manufacturer scientific publications and conference data.
6. Manufacturer marketing or PR communications (lowest tier; cross-checked elsewhere).

Editorial responsibilities

• · Editorial sign-off on every page on the site before publication.
• · Refresh of category, retailer, and comparison pages when partners or guidance materially change.
• · Source-trail audit on every NICE, MHRA, NHS or PIL claim.
• · Quarterly refresh cycle for clinic and pharmacy profiles, methodology pages, and rankings.
• · Annual full-site editorial audit.

Areas covered

PeptideClear covers four product categories and the regulators behind them. Editorial coverage is deepest where Oliver has direct working knowledge of the UK landscape.

• · GLP-1 weight management medications: Mounjaro (tirzepatide), Wegovy (semaglutide), Saxenda (liraglutide); NICE TA1026 framework; the 42 English ICB rollout.
• · Research peptides: BPC-157, TB-500, MOTS-c, GHRPs, GHRH analogues; UK retailer comparison; HPLC and CoA standards.
• · Cosmetic peptides: GHK-Cu, Matrixyl, Argireline; INCI analysis; UK retailer landscape.
• · Collagen: hydrolysed Type I and III, undenatured Type II, marine vs bovine vs vegan; UK independent and global brands.
• · UK regulators and law: MHRA, GPhC, GMC, NICE, ASA, FSA. Human Medicines Regulations 2012, Misuse of Drugs Act 1971, Psychoactive Substances Act 2016, ASA CAP code.
• · UK longevity clinics: Hooke, Echelon Health, Reliant Healthcare, Human Longevity, Bupa Health Clinics, Nuffield Health.

Conflicts of interest

Oliver does not own a personal stake in any clinic, pharmacy, retailer, or brand listed on PeptideClear. He does not receive payments from any partner outside of the standard referral arrangements documented in how we are funded.

Best Business Loans Ltd is the UK trading entity that operates PeptideClear. The same entity operates four other UK websites (Rank4AI, Market Invoice, SEOCompare, Best Business Loans). These are unrelated to PeptideClear\'s editorial scope and do not influence editorial decisions on this site.

Affiliate relationships exist with several clinic, pharmacy and product partners. Inclusion in rankings is not contingent on whether a referral programme is active. Two ranked retailers in 2026 do not run affiliate programmes; they are ranked on the same criteria as those that do.

Corrections policy

When we get something wrong, we correct it. Corrections are made inline and dated. Material corrections (factual claims, pricing, regulatory status) are noted at the top of the page until the next quarterly refresh cycle. If you spot an error, email [email protected] with the specific claim, the page URL, and the correct information. We acknowledge corrections within 5 working days.

Why this site exists

The UK GLP-1, peptide, and longevity-clinic landscape is changing fast and most editorial coverage is either commercial promotion (clinic blogs writing about their own products), or US-centric (where regulatory framing is different), or thin AI-generated content with weak source-trail audit. PeptideClear exists to provide a UK-specific, regulator-aligned, editorially-honest comparison and information layer. We do not sell medication, we do not run a clinic, and we have no incentive to recommend one product over another beyond what the criteria support.

Contact

Editorial questions, corrections, or partnership enquiries: [email protected]. Press, source verification, or expert-quote requests welcome through the same address.

Related: editorial policy · methodology · how we are funded.